Product Description
Overall, the global left atrial appendage closure device market was valued at $1.4 billion in 2023. This is expected to increase over the forecast period at a CAGR of 11.8% to reach $3.1 billion.
The full report suite on the global market for left atrial appendage (LAA) closure device includes endocardial and epicardial devices. Boston Scientific, Abbott, and AtriCure were the top three market share leaders in the global left atrial appendage closure device market.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2030, and Historical Data to 2020
- Recent Mergers & Acquisitions
- Disease Overviews
- Company Profiles, Product Portfolios, and SWOT for Top Competitors
Global Left Atrial Appendage Closure Device Market Insights
The LAA closure device market, while limited in active companies, is witnessing burgeoning interest, signaling a shift towards heightened competition and more aggressive pricing strategies. As awareness and diagnosis of clotting risks associated with the LAA increase, the market’s valuation is poised to climb. Both types of devices will see escalated usage, yet it’s the endocardial device that is projected to spearhead this growth, reshaping market dynamics significantly.
MARKET SHARE INSIGHTS
In 2023, Boston Scientific led the global market for left atrial appendage (LAA) closure devices, mainly through its WATCHMAN™ series, a favored endocardial option. As regulatory approvals for competitors’ devices emerge, Boston Scientific is expected to face increased market competition.
Following closely, Abbott secured the second position in the LAA market with its Amplatzer™ Amulet™ LAA Occluder. Abbott’s established product line suggests potential growth in its market share in the foreseeable future.
AtriCure ranked third, offering a range of devices under its AtriClip® line, positioned as the epicardial option in the market. With its extensive product portfolio, AtriCure is anticipated to sustain its market share in the years ahead.
MARKET SEGMENTATION SUMMARY
- Endocardial LAA Device
- Epicardial Clip LAA Device
- Epicardial Suture LAA Device
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Regions | North America(Canada, United States) Latin America(Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe(Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe(Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East(Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific(Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Mongolia, Malaysia, Myanmar, New Zealand, Philippines, Pakistan, Singapore, South Korea, Taiwan, Thailand, Uzbekistan, Vietnam) Africa(Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2023 |
| Forecast | 2024-2030 |
| Historical Data | 2020-2023 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
